NEW YORK, Aug. 24, 2017 (GLOBE NEWSWIRE) -- Bromodomain and extra-terminal (BET) inhibitors are small molecule inhibitors including bromodomain 2 (BRD2), bromodomain 3 (BRD3), bromodomain 4 (BRD4) and bromodomain testis (BRDT), which have anti-proliferating properties. These targets of inhibitors are supposed to bind with myc gene, which is a most desired target for cancer therapeutics. BET inhibitors are first-in-class targeted therapies that directly target bromodomain proteins to deliver a new therapeutic prospect as inhibition of epigenetic regulators.
Browse full Report Summary on “Global Bromodomain and Extra-Terminal (BET) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” at: https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis
BET inhibitor constitutes that class of drugs that prevents interactions between BET proteins, and transcription factors and acetylated histone. This results in immunosuppressive and anti-cancer properties of BET inhibitor. BET inhibitors when administered, bind to acetylated lysine motifs, thus, preventing interaction between acetylated lysine and BET proteins. This disrupts the gene expression and chromatin remodeling. Inhibition of certain growth promoting genes results in reducing tumor cell growth. BET proteins play an important role in cell growth and development as transcriptional regulators. Inhibition of BET proteins offered a new therapeutic approach for the treatment of cancer, cardiovascular diseases and other diseases.
The discovery of BET proteins shows that they play a crucial role in transcriptional activation, and thus, have oncogenic potential. This has resulted in the development of several small molecule BET inhibitors. Preclinical studies have shown promising results for many indications, both in in-vitro and in-vivo studies. There are many early phase clinical trials for these inhibitors that are presently testing the efficacy of BET inhibitors.
Make an Enquiry Before Buying this Research Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=bet-inhibitors-pipeline-analysis
The BET inhibitors pipeline is very strong, with approximately 38 drug candidates in different stages of development.
Some of the key players developing BET inhibitors are Resverlogix Corp., GlaxoSmithKline plc, Bristol-Myers Squibb Company and others.
More Research Report Published by P&S
Post-Operative Pain Therapeutics Pipeline Analysis, 2017
Post-operative pain is a very common problem after any surgery and it is necessary to treat the same effectively, so that the patient is more comfortable and positive, wounds heal better, there remains less risk for heart and lung complications, and patients are less likely to develop neuropathic pain.
https://www.psmarketresearch.com/market-analysis/post-operative-pain-therapeutics-pipeline-analysis
Friedreich’s Ataxia (FRDA) Therapeutics Pipeline Analysis, 2017
Friedreich’s ataxia is diagnosed by molecular genetic testing to detect mutations in the FXN gene. The symptomatic treatment of Friedreich's ataxia includes continuous medical supervision to avoid further complications involving the spine, heart, muscles, feet, hearing and vision. Genetic counseling is also recommended for affected individuals and their families.
https://www.psmarketresearch.com/market-analysis/frda-therapeutics-pipeline-analysis
Diabetic Foot Ulcer Therapeutics Pipeline Analysis, 2017
Considerable growth is expected in the diabetic foot ulcer therapeutic pipeline, attributed to increasing prevalence of diabetes. According to the World Health Organization, the prevalence of diabetes among adults over 18 years of age, has risen from 4.7% in 1980 to 8.5% in 2014, in the U.S. Funds received or raised from various non-profit organizations such as, American Podiatric Medical Association and PAN Association, are being used to support the development of therapeutic pipeline of the diabetic foot ulcer. Many technological advancements are also contributing towards the development of diabetic foot ulcer therapeutics pipeline.
https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Abhishek
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com